Treatment of epidermal growth factor receptor antagonist-induced skin rash: Results of a survey among German oncologists

Onkologie

Volumn 33, Issue 3, 2010, Pages 94-96

  Hassel, Jessica C ^a,b   Kripp, Melanie ^b   Al Batran, Salah ^c   Hofheinz, Ralf Dieter ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Nordwest Hospital   (Germany)

Author keywords

Antibody therapy; EGFR; EGFR antagonist management; Side effects; Skin care; Toxicity

Indexed keywords

CETUXIMAB; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; HYDROCORTISONE; ISOTRETINOIN; METRONIDAZOLE; MINOCYCLINE; NADIFLOXACIN; PIMECROLIMUS;

ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG PREFERENCE; DRUG WITHDRAWAL; GERMANY; HEALTH SURVEY; HUMAN; LOCAL THERAPY; PATIENT REFERRAL; PHYSICIAN; QUESTIONNAIRE; RATING SCALE; STEROID THERAPY;

ADULT; ANTINEOPLASTIC AGENTS; COMORBIDITY; DERMATOLOGIC AGENTS; DRUG ERUPTIONS; FEMALE; GERMANY; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77949402839     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277656     Document Type: Article

References (13)

1. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
2. Lacouture ME, Melosky BL: Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett 2007;12:1-5.
3. Saltz L, Kies M, Abbruzeese JL, Azarnia N, Needle M: Presence and intensity of the cetuximab-induced acne-rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003;22:204 (Abstr 817).
4. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:391-321.
5. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, Milanesi E, Ciorba A, Paris M, Facilissimo I, Macripo G, Clerico M, Ciuffreda L: Effecacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer 2008;7:48-54.
6. Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG: Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009;115:1544-1554.
7. Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6: 803-812.
8. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T: Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
9. Lacouture ME, Mitchel EP, Shearer H, Iannotti N, Piperdi B, Pillai MV, Xu F, Yassine M: Impact of pre-emptive skin toxicity (ST) treatment (tx) on panitumumab (pmab)-related skin toxicities and quality of life (QoL) in patients (pts) with metastatic colorectal cancer (mCRC): Results from STEPP 2009. Gastrointestinal Cancers Symposium, Abstr 291.
10. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC: Rando mized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab- associated acne-like eruption. J Clin Oncol 2007;25:5390-5396.
11. Jatoi A, Nguyen PL: Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008;13:1201-1204.
12. Mitchell EP, Lacouture M, Shearer H, Iannotti N, Piperdi B, Madhavan P, Xu F, Yassine M: Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2009;27 (suppl 18S, part II):Abstr CRA4027.
13. Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, Halpern AC: A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009;61:614-620.